Last checked at 22 Apr 2015 11:23
Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)
Director's Shareholding
London: Wednesday, 22 April 2015: Chi-Med received notification on 22 April 2015 that Mr Christopher Nash, Independent Non-executive Director, has purchased 1,388 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP18.00 per share on 21 April 2015.
Following this purchase, Mr Nash is beneficially interested in 31,930 Shares, representing approximately 0.06% of the current issued share capital of Chi-Med.
Ends
Enquiries
Chi-Med Christian Hogg, CEO
| Telephone: | +852 2121 8200 |
Panmure Gordon (UK) Limited Richard Gray Andrew Potts
| Telephone: | +44 20 7886 2500 |
Citigate Dewe Rogerson Anthony Carlisle David Dible | Telephone: Mobile: Mobile: | +44 20 7638 9571 +44 7973 611 888 +44 7967 566 919 |
About Chi-Med
Chi-Med is a China-based healthcare group focused on researching, developing, manufacturing and selling pharmaceuticals and health-related consumer products. Its Drug R&D Division focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases. Its China Healthcare Division manufactures, markets and distributes prescription and over-the-counter pharmaceuticals in China. Its emerging Consumer Products Division focuses on organic and natural consumer products in Asia.
Chi-Med is majority owned by the multinational conglomerate Hutchison Whampoa Limited (SEHK:13). For more information, please visit: www.chi-med.com.